Publications

BibTex format

@article{Nambron:2016:10.1371/journal.pone.0146480,
author = {Nambron, R and Silajdzic, E and Kalliolia, E and Ottolenghi, C and Hindmarsh, P and Hill, NR and Costelloe, SJ and Martin, NG and Positano, V and Watt, HC and Frost, C and Bjorkqvist, M and Warner, TT},
doi = {10.1371/journal.pone.0146480},
journal = {PLOS One},
title = {A Metabolic Study of Huntington's Disease},
url = {http://dx.doi.org/10.1371/journal.pone.0146480},
volume = {11},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Huntington’s disease patients have a number of peripheral manifestations suggestive of metabolic and endocrine abnormalities. We, therefore, investigated a number of metabolic factors in a 24-hour study of Huntington’s disease gene carriers (premanifest and moderate stage II/III) and controls.Methods:Control (n = 15), premanifest (n = 14) and stage II/III (n = 13) participants were studied with blood sampling over a 24-hour period. A battery of clinical tests including neurological rating and function scales were performed. Visceral and subcutaneous adipose distribution was measured using magnetic resonance imaging. We quantified fasting baseline concentrations of glucose, insulin, cholesterol, triglycerides, lipoprotein (a), fatty acids, amino acids, lactate and osteokines. Leptin and ghrelin were quantified in fasting samples and after a standardised meal. We assessed glucose, insulin, growth hormone and cortisol concentrations during a prolonged oral glucose tolerance test.Results:We found no highly significant differences in carbohydrate, protein or lipid metabolism markers between healthy controls, premanifest and stage II/III Huntington’s disease subjects. For some markers (osteoprotegerin, tyrosine, lysine, phenylalanine and arginine) there is a suggestion (p values between 0.02 and 0.05) that levels are higher in patients with premanifest HD, but not moderate HD. However, given the large number of statistical tests performed interpretation of these findings must be cautious.Conclusions:Contrary to previous studies that showed altered levels of metabolic markers in patients with Huntington’s disease, our study did not demonstrate convincing evidence of abnormalities in any of the markers examined. Our analyses were restricted to Huntington’s disease patients not taking neuroleptics, anti-depressants or other medication affecting metabolic pathways. Even with the modest sample sizes studied, the lack of highly signific
AU  - Nambron,R
AU  - Silajdzic,E
AU  - Kalliolia,E
AU  - Ottolenghi,C
AU  - Hindmarsh,P
AU  - Hill,NR
AU  - Costelloe,SJ
AU  - Martin,NG
AU  - Positano,V
AU  - Watt,HC
AU  - Frost,C
AU  - Bjorkqvist,M
AU  - Warner,TT
DO  - 10.1371/journal.pone.0146480
PY  - 2016///
SN  - 1932-6203
TI  - A Metabolic Study of Huntington's Disease
T2  - PLOS One
UR  - http://dx.doi.org/10.1371/journal.pone.0146480
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367815600054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/48518
VL  - 11
ER  -

Download

Hilary Watt CStat FHEA MSc MA(Oxon) BA

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)